Core Insights - Bio-Techne Corporation (NASDAQ:TECH) is recognized as one of the top 10 life sciences stocks favored by hedge funds [1] - Analysts have provided mixed ratings, with price targets indicating potential upside for investors [2][3] Analyst Ratings - Daniel Arias from Stifel Nicolaus maintains a Hold rating, raising the price target from $60 to $65, suggesting a 13% upside potential [1] - Evercore ISI analyst Daniel Markowitz reiterates an In Line rating, increasing the price target from $62 to $68, indicating over 18% upside potential [2] Company Performance and Outlook - Despite a strong second-quarter performance, expectations for flat mid-year growth and an unchanged forecast for the upcoming year have been noted [2] - The fourth quarter guidance suggests a light market recovery, with promising FY27 organic growth projections for the company [3] Company Overview - Bio-Techne Corporation specializes in developing and marketing life sciences instruments, reagents, precision diagnostics, and related services for various markets including clinical research and gene therapy [4] - The product portfolio includes antibodies, immunoassay kits, automated protein analysis systems, hematology, and molecular diagnostic kits [4]